Physician profile
Howard M Schecht
NPI 1710984711
$183,219.18
in general payments reported to CMS, 2019-2025
77 companies · $5,244 in 2025
The $5,244 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74K · 2020: $44K · 2021: $29K · 2022: $18K · 2023: $5,712 · 2024: $7,162 · 2025: $5,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,494 · Consulting Fee: $450 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,996.36 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,493.80 |
| Consulting Fee | $450.00 |
| Education | $177.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $75,368.55 | 2019-2024 | Uplizna, Aimovig |
| Abbvie INC. | $24,312.89 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Teva Pharmaceuticals USA, INC. | $22,917.32 | 2019-2025 | Austedo Xr, Austedo, Ajovy |
| Emd Serono, INC. | $21,483.46 | 2019-2025 | Mavenclad, Mavenclad |
| Allergan, INC. | $8,546.85 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $4,603.07 | 2019-2025 | |
| Biogen, INC. | $2,709.87 | 2019-2025 | Tysabri, Vumerity, Spinraza |
| Genzyme Corporation | $2,597.78 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $2,572.17 | 2019-2025 | Rytary, Ongentys 50mg Capsules 30, Crexont |
| Mdd US Operations, LLC | $2,076.79 | 2022-2025 | Apokyn, Apokyn, Gocovri |
| E.R. Squibb & Sons, L.L.C. | $1,777.94 | 2020-2024 | Zeposia |
| Acadia Pharmaceuticals INC | $1,054.14 | 2019-2025 | Nuplazid, Daybue |
| Alexion Pharmaceuticals, INC. | $1,025.31 | 2019-2025 | Ultomiris, Soliris |
| Ucb, INC. | $1,012.71 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Genentech USA, INC. | $894.06 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $794.53 | 2020-2025 | |
| Celgene Corporation | $786.72 | 2021-2025 | Zeposia |
| Lilly USA, LLC | $744.96 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Csl Behring | $629.05 | 2019-2025 | Hizentra |
| Lundbeck LLC | $617.14 | 2019-2025 | Vyepti, Rexulti |
| Pfizer INC. | $531.12 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $495.25 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $446.02 | 2021-2022 | |
| Eisai INC. | $363.10 | 2019-2025 | |
| Tg Therapeutics, INC. | $339.67 | 2023-2025 | |
| Kyowa Kirin, INC. | $332.80 | 2020-2024 | Nourianz |
| Takeda Pharmaceuticals U.S.A., INC. | $301.10 | 2022-2025 | Hyqvia, Gammagard |
| Acorda Therapeutics, INC | $295.07 | 2019-2023 | Inbrija, Ampyra |
| Adamas Pharmaceuticals, INC. | $264.12 | 2019-2021 | |
| Horizon Therapeutics Plc | $248.73 | 2021-2023 | Uplizna |
| Vanda Pharmaceuticals INC. | $241.58 | 2024-2025 | Ponvory |
| Biohaven Pharmaceutical Holding Company Ltd. | $231.36 | 2022 | |
| Avanir Pharmaceuticals, INC. | $192.40 | 2019-2022 | |
| Neurelis, INC. | $175.10 | 2021-2025 | Valtoco |
| Biohaven Pharmaceuticals, INC. | $165.90 | 2021 | |
| Argenx US, INC. | $151.94 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Alnylam Pharmaceuticals INC. | $120.94 | 2020-2023 | Onpattro |
| Upsher-Smith Laboratories LLC | $120.57 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $115.68 | 2023-2025 | Rexulti, Nuedexta |
| Axsome Therapeutics, INC. | $99.53 | 2023-2025 | Symbravo, Sunosi |
| Jazz Pharmaceuticals INC. | $92.36 | 2019-2023 | Epidiolex |
| Assertio Therapeutics, INC. | $76.69 | 2019-2020 | |
| Banner Life Sciences, LLC | $73.65 | 2021-2023 | |
| Impel Pharmaceuticals INC. | $68.87 | 2022-2023 | Trudhesa |
| Amylyx Pharmaceuticals, INC. | $66.21 | 2023 | Relyvrio |
| Almatica Pharma LLC | $62.78 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $61.22 | 2020-2024 | Fycompa |
| Livanova USA, INC. | $60.05 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Nobelpharma America, LLC | $57.76 | 2023 | |
| Tanabe Pharma America, INC. | $53.43 | 2019 | |
| Merz Pharmaceuticals, LLC | $50.85 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Avadel Cns Pharmaceuticals, LLC | $50.31 | 2025 | Lumryz |
| Astrazeneca Pharmaceuticals Lp | $49.69 | 2021-2025 | Wainua |
| Genentech, INC. | $48.19 | 2019 | |
| Neurocrine Biosciences, INC. | $47.02 | 2020-2024 | Ingrezza |
| Bausch Health US, LLC | $45.29 | 2019 | |
| Grifols USA, LLC | $41.04 | 2020 | |
| Greenwich Biosciences, INC. | $38.66 | 2019-2020 | |
| Aprecia Pharmaceuticals, LLC | $38.53 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $38.11 | 2021 | |
| Mylan Specialty L.P. | $37.81 | 2023 | Glatiramer Acetate |
| Sanofi-Aventis U.S. LLC | $36.51 | 2020 | |
| Mallinckrodt Hospital Products INC. | $31.26 | 2021 | |
| Avion Pharmaceuticals | $28.97 | 2022-2023 | Dhivy |
| Mallinckrodt Enterprises LLC | $26.41 | 2019 | |
| Averitas Pharma INC. | $21.91 | 2024 | Qutenza |
| Nevro Corp. | $20.99 | 2021 | |
| Ani Pharmaceuticals, INC. | $19.68 | 2025 | Purified Cortrophin Gel |
| Medtronic, INC. | $18.06 | 2023 | Percept Pc Brainsense |
| Boston Scientific Corporation | $16.59 | 2024 | |
| Sumitomo Pharma America, INC. | $16.07 | 2024 | Aptiom |
| Grt US Holding, INC. | $15.51 | 2022 | |
| Hospira, INC. | $15.41 | 2024 | |
| Advanced Respiratory, INC | $14.25 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.21 | 2019 | |
| Ceribell, INC. | $10.54 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Schecht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.